rs587782228

Variant summary

Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong

The NM_001048174.2(MUTYH):​c.1393G>T​(p.Val465Phe) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000435 in 1,608,158 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V465I) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000026 ( 0 hom., cov: 30)
Exomes 𝑓: 0.000045 ( 0 hom. )

Consequence

MUTYH
NM_001048174.2 missense, splice_region

Scores

7
11
1
Splicing: ADA: 0.9999
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:13

Conservation

PhyloP100: 3.53
Variant links:
Genes affected
MUTYH (HGNC:7527): (mutY DNA glycosylase) This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 12 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF. Scorers claiming Uncertain: max_spliceai. No scorers claiming Benign.
PP5
Variant 1-45330557-C-A is Pathogenic according to our data. Variant chr1-45330557-C-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 219953.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-45330557-C-A is described in Lovd as [Likely_pathogenic]. Variant chr1-45330557-C-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MUTYHNM_001048174.2 linkc.1393G>T p.Val465Phe missense_variant, splice_region_variant Exon 15 of 16 ENST00000456914.7 NP_001041639.1 Q9UIF7-6

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MUTYHENST00000456914.7 linkc.1393G>T p.Val465Phe missense_variant, splice_region_variant Exon 15 of 16 1 NM_001048174.2 ENSP00000407590.2 Q9UIF7-6
ENSG00000288208ENST00000671898.1 linkn.1981G>T splice_region_variant, non_coding_transcript_exon_variant Exon 19 of 21 ENSP00000499896.1 A0A5F9ZGZ0

Frequencies

GnomAD3 genomes
AF:
0.0000263
AC:
4
AN:
152176
Hom.:
0
Cov.:
30
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000588
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000417
AC:
1
AN:
239690
Hom.:
0
AF XY:
0.00
AC XY:
0
AN XY:
129386
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000929
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000453
AC:
66
AN:
1455982
Hom.:
0
Cov.:
31
AF XY:
0.0000456
AC XY:
33
AN XY:
723686
show subpopulations
Gnomad4 AFR exome
AF:
0.0000300
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000568
Gnomad4 OTH exome
AF:
0.0000333
GnomAD4 genome
AF:
0.0000263
AC:
4
AN:
152176
Hom.:
0
Cov.:
30
AF XY:
0.0000269
AC XY:
2
AN XY:
74336
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000588
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000111
Hom.:
0
Bravo
AF:
0.0000151
ExAC
AF:
0.0000165
AC:
2

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Familial adenomatous polyposis 2 Pathogenic:7
Sep 11, 2024
All of Us Research Program, National Institutes of Health
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This missense variant replaces valine with phenylalanine at codon 493 in the nudix hydrolase domain of the MUTYH protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). A functional study has shown the mutant protein to be partially defective in a complementation assay in a MutY-deficient E.coli strain (PMID: 25820570). This variant has been reported in homozygous or compound heterozygous state with other pathogenic variant in individuals affected with multiple colorectal adenomas (PMID: 16557584, 17949294). It has also been reported in a heterozygous individual affected with colorectal cancer (PMID: 17931073). This variant has been identified in 4/271092 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -

Oct 16, 2015
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: c.1477G>T affects a conserved nucleotide located at the first position of exon 15, resulting in amino acid change from Val to Phe. 3/4 in-silico tools predict this variant to be damaging (SNPs&GO not captured due to low reliability index). 5/5 programs in Alamut predict that this variant does not significantly affect normal splicing. ESE finder predicts that this variant may affect ESE site of SC35. Grandval_2015 predicted that this variant leads to major loss of exon 5 and an inframe deletion (p.Val479_Met492del) based on RT-PCR product sequencing (data not shown). This variant has been reported in homozygous and compound heterozygous state in patients with atypical polyposis, colorectal adenomas, MUTYH associated polyposis. Heterozygous variant was found in 3/87104 control chromosomes at a frequency of 0.0000344 and one patient with sporadic colorectal cancer. One functional study in E.coli showed that protein with this variant partially lost the normal function in suppressing spontaneous mutations (Komine_2015). However, its function in human cells is still not clear. Taken together, this variant was classified as likely pathogenic. -

May 04, 2016
Counsyl
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aug 21, 2023
Baylor Genetics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aug 22, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.Val493Phe variant (also known as p.Val479Phe in the literature) in MUTYH has been reported in 1 compound heterozygous individual with MUTYH-associated attenuated familial adenomatous polyposis (FAP; Aretz 2006), 1 compound heterozygous individual with colorectal adenomas (Reggoug 2009), 1 homozygous individual with sporadic colorectal cancer (CRC; Kury 2007), and 1 heterozygous individual with CRC with no second allele specified (Kury 2007). This variant has also been reported in ClinVar (Variation ID 219953). This variant has been identified in 3/15010 European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs587782228). This frequency is low enough to be consistent with the frequency of MUTYH-related attenuated FAP in the general population. In vitro functional studies provide some evidence that the p.Val493Phe variant may impact protein function (Grandval 2015, Komine 2015). Computational prediction tools and conservation analysis suggest that the p.Val493Phe variant may impact the protein. In summary, although additional studies are required to fully establish its clinical significance, the p.Val493Phe variant is likely pathogenic. ACMG/AMP Criteria applied: PM3_Strong, PS3_Moderate, PP3 -

Jan 29, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 493 of the MUTYH protein (p.Val493Phe). RNA analysis indicates that this missense change induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs587782228, gnomAD 0.002%). This missense change has been observed in individuals with polyposis or colorectal cancer and/or small cell lung cancer (PMID: 16557584, 17931073, 17949294, 19806110, 20618354, 23729658, 33504652). This variant is also known as c.1435G>T (p.Val479Phe). ClinVar contains an entry for this variant (Variation ID: 219953). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects MUTYH function (PMID: 25820570). Studies have shown that this missense change results in skipping of exon 15 skipping, but is expected to preserve the integrity of the reading-frame (internal data). For these reasons, this variant has been classified as Pathogenic. -

Jan 06, 2022
Revvity Omics, Revvity
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Pathogenic:2
May 06, 2021
GeneDx
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Not observed at a significant frequency in large population cohorts (Lek 2016); Reported in the homozygous or compound heterozygous state in at least 3 individuals with multiple colorectal adenomas, with or without colorectal cancer (Aretz 2006, Buecher 2008, Reggoug 2009); Published functional studies demonstrate a damaging effect: partially defective base excision repair activity in a yeast-based complementation assay (Komine 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as c.1435G>T, p.Val479Phe; This variant is associated with the following publications: (PMID: 18787472, 29684080, 22493355, 22538434, 27631816, 21279954, 25368107, 26689913, 25820570, 20618354, 19806110, 16557584, 17931073, 17949294) -

Feb 28, 2024
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The MUTYH c.1477G>T (p.Val493Phe) variant has been reported in the published literature in individuals affected with colorectal polyposis, adenomas, and/or cancer (PMID: 16557584 (2006), 17931073 (2007), 17949294 (2007), 19806110 (2009), 20618354 (2010)). It has also been reported in individuals affected with renal clear cell carcinoma (PMID: 26689913 (2015)), breast cancer (PMID: 33471991 (2021), see also LOVD (https://databases.lovd.nl/shared/variants/MUTYH)), and small cell lung cancer (PMID: 33504652 (2021)). In addition, it has been identified in reportedly healthy individuals (PMID: 17931073 (2007), 33471991 (2021), see also LOVD (https://databases.lovd.nl/shared/variants/MUTYH)). Functional studies report this variant results in a MUTYH protein with partially defective function (PMID: 25820570 (2015)) and causes exon 15 skipping (PMID: 25368107 (2015)). The frequency of this variant in the general population, 0.000033 (4/123030 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as pathogenic. -

Hereditary cancer-predisposing syndrome Pathogenic:2
Dec 11, 2024
Color Diagnostics, LLC DBA Color Health
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This missense variant replaces valine with phenylalanine at codon 493 in the nudix hydrolase domain of the MUTYH protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function. A functional study has shown the mutant protein to be partially defective in a complementation assay in a MutY-deficient E.coli strain (PMID: 25820570). This variant has been reported in the homozygous or compound heterozygous state in individuals affected with multiple colorectal adenomas (PMID: 16557584, 17949294). It has also been reported in a heterozygous individual affected with colorectal cancer (PMID: 17931073). This variant has been identified in 4/271092 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -

May 15, 2023
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.1477G>T pathogenic mutation (also known as p.V493F) is located in coding exon 15 of the MUTYH gene. The valine at codon 493 is replaced by phenylalanine, an amino acid with highly similar properties. This change occurs in the first base pair of coding exon 15 and this nucleotide position is highly conserved in available vertebrate species. This alteration has been identified both in conjunction with a pathogenic MUTYH mutation and in the homozygous state in polyposis patients (Aretz S et al. Int. J. Cancer. 2006 Aug 15;119:807-14; Olschwang S et al. Genet. Test. 2007;11:315-20; Ambry internal data). In addition, this alteration was classified by a functional complementation assay as partially defective (Komine K et al. Hum. Mutat. 2015 Jul;36:704-11). Of note, this alteration is also designated as p.V479F (c.1435G>T) in published literature. In silico splice site analysis predicts that this alteration may weaken the native splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). As such, this alteration is classified as a disease-causing mutation. -

Gastric cancer;C3272841:Familial adenomatous polyposis 2 Pathogenic:1
Jul 21, 2021
Fulgent Genetics, Fulgent Genetics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

MUTYH-related disorder Pathogenic:1
Jul 17, 2023
PreventionGenetics, part of Exact Sciences
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The MUTYH c.1477G>T variant is predicted to result in the amino acid substitution p.Val493Phe. This variant was reported in multiple individuals with MUTYH-associated polyposis, colorectal cancer, or small cell lung cancer (see for example Aretz et al 2006. PubMed ID: 16557584; Küry et al 2007. PubMed ID: 17931073; Olschwang et al 2007. PubMed ID: 17949294; Reggoug et al 2009. PubMed ID: 19806110; Morak et al 2010. PubMed ID: 20618354; Tlemsani et al 2021. PubMed ID: 33504652). A published functional study demonstrated the damaging effect of this variant (Komine K et al 2015. PubMed ID: 25820570). This variant is also known as c.1435G>T (p.Val479Phe). This variant is reported in 0.0033% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-45796229-C-A). This variant is interpreted as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.74
BayesDel_addAF
Pathogenic
0.46
D
BayesDel_noAF
Pathogenic
0.43
CADD
Uncertain
25
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.52
.;.;.;.;.;.;D;.;.;.;.;D
Eigen
Uncertain
0.48
Eigen_PC
Uncertain
0.48
FATHMM_MKL
Uncertain
0.94
D
LIST_S2
Uncertain
0.91
.;.;D;.;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
0.43
D
MetaRNN
Pathogenic
0.96
D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
0.95
D
MutationAssessor
Uncertain
2.5
.;.;.;.;.;.;M;.;.;.;.;.
PrimateAI
Uncertain
0.57
T
PROVEAN
Uncertain
-3.5
D;D;D;D;D;D;D;D;D;D;D;.
REVEL
Pathogenic
0.82
Sift
Uncertain
0.0010
D;D;D;D;D;D;D;D;D;D;D;.
Sift4G
Uncertain
0.0030
D;D;D;D;D;D;D;D;D;D;D;D
Polyphen
0.50, 0.86, 0.33
.;.;.;.;.;.;P;P;.;.;B;.
Vest4
0.80
MutPred
0.83
.;.;.;.;.;.;.;.;.;.;Loss of MoRF binding (P = 0.1201);.;
MVP
0.95
MPC
0.62
ClinPred
0.97
D
GERP RS
5.5
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.9
Varity_R
0.57
gMVP
0.72

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
0.96
SpliceAI score (max)
0.43
Details are displayed if max score is > 0.2
DS_AL_spliceai
0.43
Position offset: 0

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs587782228; hg19: chr1-45796229; API